GlassScriptPhysician profile
Richa Mittal
NPI 1700077252
$8,376.94
in general payments reported to CMS, 2019-2025
8 companies · $7,405 in 2025
The $7,405 reported for 2025 was more than what 79% of Obesity Medicine (Internal Medicine) providers received nationally (typical 2025 total: $202).
See the full distribution for Obesity Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $48.34 · 2021: $148 · 2022: $58.92 · 2023: $150 · 2024: $245 · 2025: $7,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,300 · Travel and Lodging: $766 · Food and Beverage: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,300.00 |
| Travel and Lodging | $766.25 |
| Food and Beverage | $733.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $7,266.02 | 2024-2025 | Zepbound, Jardiance |
| Novo Nordisk INC | $901.77 | 2019-2025 | Wegovy |
| Vivus LLC | $56.45 | 2024 | Qsymia |
| Kvk-Tech, INC. | $50.95 | 2021 | |
| Boston Scientific Corporation | $40.62 | 2022 | |
| Abbott Laboratories | $34.37 | 2022-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $15.21 | 2025 | Korlym |
| Nalpropion Pharmaceuticals LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.